A recombinant BCG vaccine generates a Th1-like response and inhibits IgE synthesis in BALB/c mice
Article first published online: 25 DEC 2001
Volume 97, Issue 3, pages 515–521, July 1999
How to Cite
Kumar, Behera, Matsuse, Lockey and Mohapatra (1999), A recombinant BCG vaccine generates a Th1-like response and inhibits IgE synthesis in BALB/c mice. Immunology, 97: 515–521. doi: 10.1046/j.1365-2567.1999.00782.x
- Issue published online: 25 DEC 2001
- Article first published online: 25 DEC 2001
The tubercle vaccine, bacille Calmette–Guérin (BCG), is a strong inducer of T-helper type 1 (Th1) responsiveness, and it has been suggested that recombinant BCG (rBCG), which produces and secretes antigens, may be used to prevent allergic diseases. The effects of rBCG vaccination on allergic responses in a murine model were examined in this study. A BCG–Escherichia coli shuttle vector was developed with the promoter and signal sequence of the α-antigen of Mycobacterium bovis, and the vector was tested using E. coliβ-galactosidase as the model antigen and allergen. This vector enabled the expression of the E. coliβ-galactosidase gene in BCG, which was detected in its protein extract by immunoblotting analysis. Vaccination of mice with a single dose of 106 recombinant BCG generated a β-galactosidase-specific antibody response. The splenocytes of vaccinated mice compared with controls produced significantly higher amounts of interferon-γ (IFN-γ) (P<0·01) and interleukin-2 (IL-2) (P<0·05) and lower amounts of IL-5 (P<0·01). Mice vaccinated with rBCG had significantly less (P<0·01) serum IgE compared with controls. These results together demonstrate that rBCG secreting antigens or allergens may be utilized for the induction of a Th1-like response and the down-regulation of IgE antibody response.